Early withdrawal immunosuppression improved mixed chimerism in stem cell transplantation for pediatric aplastic anemia

No abstract is available for this paper.

• Publication year

  2025

• Venue

  International journal of hematology

• Publication date

  2025-05-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12185-025-03971-9PMID 40408010
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Recent advances in the diagnosis and treatment of pediatric acquired aplastic anemia

  2023cited by this paper
• Definitions, incidence and outcome of poor graft function after hematopoietic cell transplantation: A systematic review and meta-analysis.

  2023influential reference
• T-cell Depleted Peripheral Blood versus Unmanipulated Bone Marrow in Matched Sibling Transplantation for Aplastic Anemia.

  2023cited by this paper
• Retrospective Comparison of Efficacy and Safety of Rabbit Anti-Thymocyte Globulin and Porcine Anti-Lymphocyte Globulin in Patients With Acquired Aplastic Anemia Undergoing Hematopoietic Stem Cell Transplantation From Matched Sibling Donors

  2022cited by this paper
• Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy.

  2021cited by this paper
• Mixed chimerism after allogeneic hematopoietic stem cell transplantation for severe aplastic anemia

  2021cited by this paper
• Optimizing conditioning regimen with low-dose irradiation or busulfan enables the outcome of transplantation from a 6–7/8 HLA-matched donor comparable to that from an 8/8 HLA-matched unrelated donor in severe aplastic anemia patients under 40 years

  2021cited by this paper
• Conditioning regimen for allogeneic bone marrow transplantation in children with acquired bone marrow failure: fludarabine/melphalan vs. fludarabine/cyclophosphamide

  2020cited by this paper
• Aplastic Anemia

  2020cited by this paper
• Haploidentical hematopoietic stem cell transplantation in aplastic anemia: a systematic review and meta-analysis of clinical outcome on behalf of the severe aplastic anemia working party of the European group for blood and marrow transplantation (SAAWP of EBMT)

  2020cited by this paper
• Shortened-duration immunosuppressive therapy after nonmyeloablative, related HLA-haploidentical or unrelated peripheral blood grafts and post-transplantation cyclophosphamide.

  2020cited by this paper
• Premature cyclosporine cessation and TBI-containing conditioning regimen increase the risk of acute GvHD in children undergoing unrelated donor hematopoietic stem cell transplantation.

  2019cited by this paper
• Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia.

  2019influential reference
• Allogeneic hematopoietic stem cell transplantation for aplastic anemia with pre‐transplant conditioning using fludarabine, reduced‐dose cyclophosphamide, and low‐dose thymoglobulin: A KSGCT prospective study

  2019cited by this paper
• Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study

  2019cited by this paper
• Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation.

  2018cited by this paper
• Aplastic Anemia

  2018cited by this paper
• Updated Guidelines for the Treatment of Acquired Aplastic Anemia in Children

  2018cited by this paper
• Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia

  2017cited by this paper
• Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant

  2015cited by this paper
• Outcomes of donor lymphocyte infusion for treatment of mixed donor chimerism after a reduced-intensity preparative regimen for pediatric patients with nonmalignant diseases.

  2015cited by this paper
• National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease

  2015cited by this paper
• Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study.

  2015cited by this paper
• A combination of fludarabine, half-dose cyclophosphamide, and anti-thymocyte globulin is an effective conditioning regimen before allogeneic stem cell transplantation for aplastic anemia

  2014cited by this paper
• Long-term outcome of childhood aplastic anemia patients who underwent allogeneic hematopoietic SCT from an HLA-matched sibling donor in Japan

  2013cited by this paper
• How I manage aplastic anaemia in children

  2012cited by this paper
• Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels.

  2012cited by this paper
• How I treat acquired aplastic anemia.

  2012cited by this paper
• Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working party

  2010cited by this paper
• Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA

  2009cited by this paper
• Guidelines for the diagnosis and management of aplastic anaemia

  2009cited by this paper
• National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

  2005cited by this paper
• How and when should we monitor chimerism after allogeneic stem cell transplantation?

  2005cited by this paper
• Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long‐term follow‐up

  2005cited by this paper
• Fludarabine, cyclophosphamide plus thymoglobulin conditioning regimen for unrelated bone marrow transplantation in severe aplastic anemia

  2004cited by this paper
• 1994 Consensus Conference on Acute GVHD Grading.

  1995cited by this paper
• Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia.

  1994cited by this paper
• Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate.

  1992cited by this paper
• Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease.

  1986cited by this paper
• Cardiotoxicity associated with high-dose cyclophosphamide therapy.

  1981cited by this paper

• No citing papers are available for this paper.